<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tissue <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion evokes toxic and harmful biochemical processes such as <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to investigate the indices of tissue damage in rat liver and brain after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion injury of these organs, and to study prospective cytoprotection of molecules such as the novel anti-inflammatory N-(2-thiolethyl)-2-(2-[N'-(2,6-dichlorophenyl)amino] <z:chebi fb="1" ids="30396">phenyl</z:chebi>)<z:chebi fb="0" ids="27856">acetamide</z:chebi> (compound 1) and <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Two experimental models were studied: firstly, 30 min liver <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> via hepatoduodenal ligament clamping followed by 60 min reperfusion; and secondly, 45 min <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> via bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 90 min reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Compound 1 and <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi> were administered intraperitoneally before induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We hereby report that compound 1, a molecule that combines potent in-vitro <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and in-vivo anti-inflammatory activity with low gastrointestinal toxicity, offered protection in-vivo against liver or brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion-induced damage </plain></SENT>
<SENT sid="5" pm="."><plain>Both compound 1 and <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi> prevented changes in <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation in the rat liver and brain tissue and in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF-alpha) levels in brain </plain></SENT>
<SENT sid="6" pm="."><plain>Also compound 1 attenuated <z:chebi fb="0" ids="16856">glutathione</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath>, evoked by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion, in the rat brain but not in the liver </plain></SENT>
<SENT sid="7" pm="."><plain>These results could be explained on the basis of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi>/anti-inflammatory properties of compound 1 and suggest its beneficial effect and potential therapeutic use in post-ischaemic injury </plain></SENT>
</text></document>